

# Index

- Absorption, drug
  - bioavailability and, 18
  - critical care settings and, 29
  - oral, 17
  - percutaneous, 17–18
  - rectal, 18
- ACE inhibitors
  - advantages/disadvantages of, 227
  - bumetanide and, 123
  - captopril, 78–81
  - CHF and, 28–29
  - CYP drug interactions and, 23
  - enalapril, 78, 81–84
  - hydrochlorothiazide and, 130
  - lisinopril, 78, 85–88
  - liver disease and, 26
  - pulmonary hypertension and, 238
  - renal disease and, 28
  - spironolactone and, 133
- Acetaminophen
  - fenoldopam and, 113
  - renal disease and, 27
- Acetazolamide
  - drug interactions/diluents, 136
  - indication, 134
  - mechanism/dosing/pharmacokinetics, 135
  - warnings, 135–136
- Action potential, 1, 2–3
- Adalat CC. *See* Nifedipine
- Adenosine, 182–184
- Administration. *See specific drug*
- Adrenaline. *See* Epinephrine
- $\alpha$ -adrenergic agonists/blocking agents, 43
- Adrenergic agonist agents
  - dobutamine, 40–41
  - dopamine, 41–44
  - norepinephrine, 50–52
- $\beta$ -adrenergic agonists, 43
- $\beta$ -adrenergic blocking agents
  - dobutamine and, 40
  - dopamine and, 43
  - isoproterenol and, 49
- Adrenoceptor antagonists
  - phenoxybenzamine, 78, 107–109
  - phentolamine, 78, 110–112
- ADRs. *See* Adverse drug reactions
- Adverse drug reactions (ADRs)
  - challenges regarding, 339–340
  - definitions of, 339
  - drug classes associated with/types of, 340
  - statistics on, 338
- Adverse effects. *See specific drug*
- Afedital. *See* Nifedipine
- Afterload
  - cardiac physiology and, 3, 5, 6–7
  - pressure-volume loops and, 8, 9–10
- $\alpha$ -agonists, 30
- $\beta$ -agonists, 227
- Alcohols
  - percutaneous absorption and, 17–18
  - vasopressin and, 57
- Alemtuzumab, 208–210
- Allopurinol
  - chlorothiazide and, 129
  - metolazone and, 131
  - renal disease and, 27
- Alteplase, 248–250
- Amiloride, 133–134
- Aminocaproic acid, 251–252
- Aminoglycosides
  - bumetanide and, 123
  - critical care settings and, 29
  - drug distribution and, 19
  - ethacrynic acid and, 127
  - furosemide and, 121
  - renal excretion and, 25
  - torsemide and, 125
- Amiodarone
  - CHF and, 29
  - CYP drug interactions and, 23, 25
  - diluents, 173

- Amiodarone (*Continued*)  
 drug interactions, 172  
 indication, 170  
 losartan and, 91  
 mechanism/dosing/pharmacokinetics/  
 monitoring, 171  
 warnings, 172–173
- Amlodipine (Norvasc)  
 diluents/concentrations, 97  
 dosing/pharmacokinetics/monitoring  
 parameters, 95  
 indication, 94  
 liver disease and, 26–27  
 mechanism of action, 78, 94–95  
 warnings/drug interactions, 96
- Amrinone. *See* Inamrinone/amrinone
- Anaphylactic reactions/shock, 46
- Anesthetic agents  
 dexmedetomidine, 294–300  
 dobutamine and, 40  
 etomidate, 284–288  
 fentanyl, 303–306  
 halothane/isoflurane/sevoflurane/  
 desflurane, 310–314  
 ketamine, 289–294  
 metaraminol and, 61  
 midazolam, 307–310  
 propofol, 280–284  
 remifentanyl, 300–303
- Angiotensin II receptor blockers, 78,  
 88–91
- $\alpha$ -antagonists, 227
- Antiarrhythmic medications  
 action potential and, 2  
 adenosine, 182–184  
 atropine, 184–185  
 CHF and, 29  
 class IA, 150–155  
 disopyramide, 154–155  
 procainamide, 152–154  
 quinidine, 150–152  
 class IB, 155–160  
 lidocaine, 156–157  
 mexiletine, 157–158  
 phenytoin, 158–160  
 class IC, 160–163  
 flecainide, 160–161  
 propafenone, 161–163  
 class II ( $\beta$ -blockers), 163–170  
 atenolol, 166–167  
 esmolol, 163–164  
 metoprolol, 167–169  
 nadolol, 169–170  
 propranolol, 164–166  
 class III, 170–179  
 amiodarone, 170–173  
 bretylium, 176–177  
 ibutilide, 177–179  
 sotalol, 173–176  
 class IV (calcium channel blockers),  
 179–182  
 diltiazem, 181–182  
 verapamil, 179–181  
 CYP drug interactions and, 24  
 digoxin, 35–39  
 magnesium sulfate, 185–187
- Antibiotics, 340
- Antibodies to IL2R and, 190  
 basiliximab, 210–212  
 daclizumab, 212–213
- Anticoagulants  
 alteplase, 248–250  
 aminocaproic acid, 251–252  
 aprotinin, 252–255  
 argatroban, 255–257  
 aspirin, 257–260  
 clopidogrel, 260–262  
 dipyridamole, 262–264  
 enoxaparin, 264–267  
 heparin, 267–269  
 lepirudin, 269–272  
 liothyronine and, 66  
 protamine, 272–274  
 spironolactone and, 133  
 tranexamic acid, 274–275  
 warfarin, 275–278
- Anticoagulation, 238
- Anticonvulsants, 340
- Antidepressants, 30
- Antifungal agents, 340
- Antimetabolites  
 AZA, 190, 191, 198–200  
 mycophenolate mofetil, 190, 191,  
 200–202
- Antineoplastic agents, 340
- Antiplatelets. *See* Anticoagulants
- Antithrombotics. *See* Anticoagulants
- Aprotinin, 252–255
- Argatroban, 255–257
- Aspirin, 257–260
- Atenolol  
 calcium chloride and, 64  
 as class II antiarrhythmic, 166–167  
 renal disease and, 28
- Atgam. *See* Equine antithymocyte  
 globulin

- Atorvastatin  
  CYP drug interactions and, 24  
  lipid lowering and, 322–325
- Atrial natriuretic peptide, 236
- Atrioventricular (AV) node, 1, 2
- Atropine  
  as antiarrhythmic, 184–185  
  metaraminol and, 61
- Atropine-resistant bradycardia, 46
- Automaticity, 3–4
- AV. *See* Atrioventricular node
- AZA. *See* Azathioprine
- Azathioprine (AZA), 190, 191, 198–200
- Azole antifungals  
  amlodipine and, 96  
  CYP drug interactions and, 23, 24  
  nicardipine and, 100
- Basic cardiac structure/function, 1
- Basiliximab, 210–212
- Benzodiazepines  
  digoxin interactions with, 38  
  drug distribution and, 19
- Bergamottin, 24
- Bile acid sequestrants, 319–322
- $\beta$ -blockers, 163–170  
  atenolol, 166–167  
  carvedilol, 142–145  
  CYP isoenzymes and, 20–22  
  epinephrine and, 47  
  esmolol, 147, 163–164  
  fenoldopam and, 113  
  mechanisms/principles regarding,  
    139–140  
  metoprolol, 140–142, 167–169  
  nadolol, 169–170  
  nifedipine and, 93  
  nitroglycerin and, 103  
  pharmacogenomics and, 30  
  propranolol, 145–147, 164–166  
  pulmonary hypertension and, 238  
  renal disease and, 28
- $\alpha$ -blocking agents, 47
- Body fat/water, 19
- Bradyarrhythmias, 4, 46
- Bretylum  
  as class III antiarrhythmic, 176–177  
  metaraminol and, 61  
  phenylephrine and, 59
- Bumetanide  
  diluent, 124  
  drug interactions, 123  
  indication/mechanism/dosing, 122  
  pharmacokinetics, 122–123  
  warnings, 123–124
- Bundle of His, 1, 2
- Calcineurin inhibitor (CNI)  
  cyclosporine as, 190, 191, 193–196  
  heart transplantation and, 190, 193–198  
  tacrolimus as, 190, 191, 196–198
- Calcium antagonists, 38
- Calcium channel blockers  
  advantages/disadvantages of, 227  
  amlodipine, 78, 94–97  
  calcium chloride and, 64  
  CYP isoenzymes and, 20–22  
  diltiazem, 181–182  
  liver disease and, 26  
  nicardipine, 78, 97–100  
  nifedipine, 78, 91–94  
  nitroglycerin and, 103  
  pulmonary hypertension and, 239  
  verapamil, 179–181
- Calcium chloride  
  adverse effects, 64–65  
  diluent, 65  
  indication, 62–63  
  mechanisms/dosing, 63  
  pharmacokinetics/drug interactions, 64
- Capoten. *See* Captopril
- Captopril (Capoten)  
  CHF and, 29  
  diluent/concentrations, 81  
  dosing, 79  
  indication/mechanism, 78  
  monitoring parameters/warnings/drug  
    interactions, 80  
  pharmacokinetics, 79–80
- Carbamazepine  
  nicardipine and, 100  
  vasopressin and, 57
- Carbonic anhydrase inhibitors, 134–136
- Cardene, Cardene I.V., Cardene SR. *See*  
  Nicardipine
- Cardiac physiology  
  action/resting potentials and, 2–3  
  afterload and, 3, 5, 6–7  
  automaticity and, 3–4  
  basic structure/function of, 1  
  contractility and, 3, 5, 6, 7, 8, 9–10  
  dysrhythmias and, 4–5  
  echocardiographic assessment of,  
    8, 11  
  electromechanical coupling and, 4  
  electrophysiology and, 1–2

- Cardiac physiology (*Continued*)  
pediatric heart and, 11–12  
preload and, 3, 5–6, 7  
pressure-volume loops and, 8, 9–10  
shunt lesions and, 12–15
- Cardiovascular drug ADRs, 340
- Carvedilol  
CYP drug interactions and, 23  
dosing, 143–144  
indication, 142–143  
liver disease and, 26  
mechanism of action, 143  
pharmacokinetics/drug interactions, 144  
warnings, 144–145
- Central venous pressure (CVP), 6
- Chemotherapeutic agents, 30
- CHF. *See* Congestive heart failure
- Chlorothiazide  
dosing, 127–128  
drug interactions/diluents, 129  
indication/mechanism of action, 127  
pharmacokinetics/warnings, 128
- Chlorpropamide, 57
- Cholesterol absorption inhibitor, 235–326
- Cholestyramine, 319–322
- Cimetidine  
CYP drug interactions and, 23, 24  
nifedipine and, 93
- Clofibrate, 57
- Clopidogrel, 260–262
- CNI. *See* Calcineurin inhibitor
- Codeine  
CYP drug interactions and, 24  
pharmacogenomics and, 30
- Colesevelam, 319–322
- Colestipol, 319–322
- Compatible diluent. *See specific drug*
- Computerized Provider Order Entry (CPOE)  
benefits from, 335  
medication errors and, 334, 335–336
- Congestive heart failure (CHF), 28–29  
adult v. pediatric, 139  
captopril and, 78  
digoxin and, 35–36  
enalapril and, 81  
furosemide and, 120  
lisinopril and, 85
- Contractility  
cardiac physiology and, 3, 5, 6, 7, 8, 9–10  
echocardiographic assessment of, 8, 11  
Frank-Starling curve and, 7  
pressure-volume loops and, 8, 9–10
- Contraindications. *See specific drug*
- Corticosteroids  
ADRs and, 340  
heart transplantation and, 190–193  
percutaneous absorption and, 17–18  
pharmacogenomics and, 30
- Cozaar. *See* Losartan
- CPOE. *See* Computerized Provider Order Entry
- Critical care settings, 29–30
- CVP. *See* Central venous pressure
- Cyclosporine  
acetazolamide and, 136  
amiloride and, 134  
amlodipine and, 96  
chlorothiazide and, 129  
CNI and, 190, 191, 193–196  
CYP drug interactions and, 24  
heart transplantation and, 193–196  
hydrochlorothiazide and, 130  
nicardipine and, 100  
nifedipine and, 93
- CYP isoenzymes  
age regarding, 22–23  
drug elimination and, 20–23  
drug interactions and, 23–25
- Daclizumab, 212–213
- Demeclocycline, 57
- Desflurane  
correlated with age, 311  
drug interactions, 313  
indication/dosing, 310  
pharmacokinetics, 312  
poisoning/diluents, 314  
systemic/adverse effects, 312–313
- Dexmedetomidine  
concentrations/diluents, 299–300  
dosing, 295–296  
drug interactions, 296–297  
future of, 300  
indication, 294  
mechanism of action, 294–295  
pharmacokinetics, 296  
systemic/adverse effects  
cardiovascular, 297–298  
central nervous system, 298  
hepatic/renal/other, 299  
respiratory, 298–299
- Dialysis, 27–28

- Diazepam, 18
- Digoxin  
adverse effects, 38–39  
amiloride and, 134  
bumetanide and, 123  
calcium chloride and, 64  
concentration profile after oral  
dose, 37–38  
dosing, 36–37  
drug interactions/contraindications, 38  
furosemide and, 121  
indication, 35–36  
liothyronine and, 66  
mechanisms of action, 36  
metolazone and, 131  
nicardipine and, 100  
nifedipine and, 93  
pharmacokinetics, 37  
poisoning/compatible diluents, 39  
pulmonary hypertension and, 238  
renal disease and, 28  
spironolactone and, 133  
torsemide and, 125
- Diltiazem  
as class IV antiarrhythmic, 181–182  
CYP drug interactions and, 23, 24
- Dipyridamole, 236, 262–264
- Disopyramide, 154–155  
CYP drug interactions and, 24  
inamrinone/amrinone and, 52–54  
liver disease and, 26
- Distribution, drug  
body water/body fat/protein-binding  
effects and, 19  
critical care settings and, 29  
Vd and, 18–19
- Diuretics  
carbonic anhydrase inhibitors,  
134–136  
acetazolamide, 134–136  
digoxin interactions with, 38  
ECMO and, 215, 219  
inamrinone/amrinone and, 52–54  
loop, 120–127  
bumetanide, 122–124  
ethacrynic acid, 125–127  
furosemide, 120–122  
torsemide, 124–125  
osmotic, mannitol, 136–138  
potassium-sparing, 132–134  
amiloride, 133–134  
spironolactone, 132–133  
pulmonary hypertension and, 238  
thiazide/thiazide-like, 127–131  
chlorothiazide, 127–129  
hydrochlorothiazide, 129–130  
metolazone, 130–131
- Dobutamine, 40–41
- Do not use list, 338
- Dopamine  
action mechanism/dosing, 42  
compatible diluents, 44  
dopexamine and, 44–45  
drug interactions/adverse effects/  
poisoning, 43  
indication, 41  
pharmacokinetics, 42–43
- Dopamine-receptor agonists, 44–45
- Dopaminergic receptor agonists, 78,  
113–115
- Dopexamine, 44–45
- Dosing. *See specific drug*
- Drug clearing  
diuretics/ranitidine/nitroglycerin/  
amrinone/milrinone/  
neuromuscular-blocking agents  
and, 215  
ECMO and, 215–222  
gentamicin/vancomycin and, 218  
heparin and, 217–218  
midazolam and, 220–221  
morphine/fentanyl/lorazepam  
and, 220  
propofol/phenobarbital and, 221
- Drug-drug interactions, 23–25. *See also  
specific drug*
- Dysrhythmias, 4–5
- Echocardiographic assessment, 8, 11
- ECMO. *See Extracorporeal membrane  
oxygenation*
- Edema  
amiloride and, 133  
bumetanide and, 122  
chlorothiazide and, 127  
ethacrynic acid and, 125  
furosemide and, 120  
hydrochlorothiazide and, 129  
mannitol and, 136  
metolazone and, 130  
spironolactone and, 132  
torsemide and, 124
- EF. *See Ejection fraction*
- Ejection fraction (EF), 11
- Electrical potential, 3
- Electromechanical coupling, 4

- Electrophysiology  
action/resting potentials and, 2–3  
automaticity and, 3–4  
basic, 1–2  
dysrhythmias and, 4–5  
electromechanical coupling and, 4
- Elimination, drug  
CYP isoenzymes and, 20–25  
drug interactions regarding, 23–25  
excretion and, 25  
metabolic functionality and, 22–23  
via metabolism/hepatic extraction, 20
- Enalapril (Vasotec), 78  
dosing, 82  
drug interactions/diluents/  
concentrations, 84  
indication, 81  
mechanism of action, 78, 81  
pharmacokinetics, 82–83  
warnings, 83–84
- Enalaprilat. *See* Enalapril
- Endothelin receptor blockers  
advantages/disadvantages of, 227  
pulmonary hypertension and, 237, 239
- Enoxaparin, 264–267
- Epinephrine (Adrenaline)  
adverse effects, 47–48  
dosing, 46–47  
indication/action mechanisms, 46  
pharmacokinetics/drug interactions, 47  
poisoning/compatible diluents/  
dilutions, 48  
vasopressin and, 57
- Equine antithymocyte globulin (Atgam),  
204–206
- Errors. *See* Medication errors
- Erythromycin, 17
- Esmolol, 147, 163–164
- Ethacrynic acid  
bumetanide and, 123  
dosing/pharmacokinetics, 126  
drug interactions/diluents, 127  
furosemide and, 121  
indication, 125  
mechanism of action, 125–126  
warnings, 126, 127
- Etomidate  
dosing, 285  
indication, 284  
mechanism of action, 284–285  
pharmacokinetics, 285–286  
systemic/adverse effects  
cardiovascular/gastrointestinal, 286  
central nervous system/respiratory/  
hepatic/renal, 287  
endocrine/other, 288
- Excretion, 25, 30
- Extracorporeal membrane oxygenation  
(ECMO)  
diuretics and, 215, 219  
drug clearing regarding, 215–222  
drug mixing regarding, 216–217  
fentanyl/morphine and, 220  
gentamicin/vancomycin and, 218  
heparin and, 217–218  
introduction to, 215  
midazolam and, 220–221  
morphine/fentanyl/lorazepam and,  
220  
plasma protein effects and, 216  
propofol/phenobarbital and, 221  
ranitidine/nitroglycerin/amrinone/  
milrinone/neuromuscular-  
blocking agents and, 215  
volume of distribution and, 215–216,  
217
- Ezetimibe, 235–326
- Felodipine  
CYP drug interactions and, 24  
liver disease and, 26–27
- Fenofibrate, 326–327
- Fenoldopam  
diluents, 114  
dosing, 113–114  
indication, 113  
mechanism of action, 78, 113  
pharmacokinetics/monitoring  
parameters/warnings/drug  
interactions, 113–114
- Fentanyl  
critical care settings and, 29  
ECMO and, 220  
nifedipine and, 93  
as sedative hypnotic/anesthetic agent,  
303–306
- Fibrates, 326–327
- Flecainide  
acetazolamide and, 136  
CHF and, 29  
as class IC antiarrhythmic, 160–161  
liver disease and, 26
- Fluconazole  
critical care settings and, 29  
CYP drug interactions and, 23  
losartan and, 91

- Fluvastatin  
  CYP drug interactions and, 24  
  lipid lowering and, 322–325
- Fosinopril  
  CHF and, 29  
  renal disease and, 28
- Frank-Starling curve, 7
- Furanocoumarins, 24
- Furosemide  
  diluent, 122  
  dosing, 120–121  
  indication/mechanism of action, 120  
  milrinone and, 54–56  
  pharmacokinetics/drug interactions, 121  
  warnings, 121–122
- Gap junctions, 1
- Gastrointestinal agents, 340
- Gemfibrozil, 326–327
- Gentamicin, 218
- Glycosides, 238
- Grapefruit, 24–25
- Halogenated anesthetic gases  
  epinephrine and, 47  
  phenylephrine and, 59  
  as sedative hypnotic/anesthetic agents, 310–314
- Halothane  
  correlated with age, 311  
  drug interactions, 313  
  indication/dosing, 310  
  pharmacokinetics, 312  
  poisoning/diluent, 314  
  systemic/adverse effects, 312–313
- Heart transplantation. *See* Transplantation, heart
- Hemodynamic calculations, 13–15
- Heparin  
  as anticoagulant/antithrombotic/antiplatelet, 267–269  
  drug clearing and, 217–218  
  nitroglycerin and, 103  
  vasopressin and, 57
- Hepatic drug elimination, 20
- High risk-high alert drugs, 335, 336
- HIV. *See* Human immunodeficiency virus protease inhibitors
- HMG CoA reductase inhibitors  
  digoxin interactions with, 38  
  for lipid lowering, 322–325
- Human immunodeficiency virus (HIV)  
  protease inhibitors, 24
- Hydralazine  
  dosing/pharmacokinetics/monitoring parameters, 118  
  drug interactions/diluent, 119  
  indication, 117  
  mechanism of action, 78, 117  
  warnings, 118–119
- Hydrochlorothiazide, 129–130
- Hydrocortisone, 57
- Hydrogenated anesthetics, 43
- Hypercholesterolemia  
  bile acid sequestrants and, 319–322  
  cholesterol absorption inhibitor and, 235–236  
  fibrates and, 326–327  
  HMG CoA reductase inhibitors and, 322–325  
  niacin and, 327–328  
  nonpharmacological lipid lowering in, 318–319  
  omega-3 fatty acids and, 329  
  risk factors for, 320  
  summary of treatments for, 321
- Hypertension. *See also* Systemic hypertension  
  amiloride and, 133  
  bumetanide and, 122  
  chlorothiazide and, 127  
  ethacrynic acid and, 125  
  furosemide and, 120  
  hydralazine and, 117  
  hydrochlorothiazide and, 129  
  metolazone and, 130  
  nicardipine and, 97  
  nitroglycerin and, 101  
  nitroprusside and, 104  
  phenoxybenzamine and, 107  
  torsemide and, 124
- Hypotension  
  metaraminol and, 60  
  phenylephrine and, 58
- Hypoxemia, 238
- Ibutilide, 177–179
- Iloprost, 235, 236
- Imipenem, 27
- Immunoglobulins, 340
- Immunosuppressive agents  
  antibodies to IL2R, 190, 210–213  
  basiliximab, 210–212  
  daclizumab, 212–213

- Immunosuppressive agents (*Continued*)  
 antimetabolites, 190, 191, 198–202  
   AZA, 190, 191, 198–200  
   mycophenolate mofetil, 190, 191, 200–202  
 CNIs, 190, 193–198  
   cyclosporine, 190, 191, 193–196  
   tacrolimus, 190, 191, 196–198  
 corticosteroids, methylprednisolone/  
   prednisone, 190–193  
 induction/maintenance therapy  
   options for, 191  
 introduction to, 190
- Immunosuppressive agents  
 mammalian target of rapamycin,  
   sirolimus, 202–204  
 monoclonal antibodies, 190, 206–210  
   alemtuzumab, 208–210  
   muromonab, 206–208  
 polyclonal antibodies, thymoglobulin  
   atgam, 204–206
- Inamrinone/amrinone, 215  
 compatible diluents, 53–54  
 dosing, 52–53  
 indication/mechanisms, 52  
 pharmacokinetics/drug interactions/  
   adverse effects, 53
- Indication. *See specific drug*
- Infant v. adult heart, 11–12
- Inhaled nitric oxide (NO), 230  
 advantages/disadvantages of, 228  
 dosage of, 232–233  
 mechanism of action and, 231–232  
 toxicity of, 233–234  
 vasodilators compared with, 235–237
- Inotropic drugs  
 digoxin, 35–39  
 dobutamine, 40–41  
 dopamine, 41–44  
 dopexamine, 44–45  
 epinephrine, 46–48  
 introduction to, 33–35, 36  
 isoproterenol/isoprenaline, 48–50  
 norepinephrine, 50–52  
 phosphodiesterase inhibitors, 52–56  
   inamrinone/amrinone, 52–54  
   milrinone, 54–56
- Insulin, 27
- Intravenous vasodilators, 234
- Isoflurane  
 correlated with age, 311  
 drug interactions, 313  
 indication/dosing, 310  
 pharmacokinetics, 312  
 poisoning/diluents, 314  
 systemic/adverse effects, 312–313
- Isoprenaline. *See Isoproterenol*
- Isoproterenol  
 adverse effects, 49–50  
 indication, 48  
 mechanisms/dosing/pharmacokinetics/  
   drug interactions, 49  
 poisoning/compatible diluents, 50  
 pulmonary hypertension and, 234  
 renal disease and, 27
- Isradipine, 26–27
- JCAHO. *See Joint Commission for the Accreditation of Healthcare Organizations*
- Joint Commission for the Accreditation of Healthcare Organizations (JCAHO)  
 do not use list by, 338  
 safety goals of, 337
- Ketamine  
 concentrations/diluents, 294  
 dosing, 290  
 drug interactions, 291  
 indication/mechanism, 289  
 pharmacokinetics, 290–291  
 poisoning information, 293–294  
 systemic/adverse effects  
   cardiovascular, 291–292  
   central nervous system, 292  
   respiratory/hepatic/renal/other, 293
- Labetalol, 47
- Lepirudin, 269–272
- Levosimendan, 67–68
- Lidocaine, 156–157  
 CHF and, 29  
 drug distribution and, 19  
 liver disease and, 26  
 V<sub>d</sub> and, 18
- Liothyronine  
 diluents, 67  
 dosing/pharmacokinetics/drug  
   interactions/adverse effects, 66  
 indication/mechanisms, 65
- Lipids. *See also Hypercholesterolemia*  
 intervention effects on, 323  
 level categorization, 319  
 lowering of, 322–325



- nonpharmacological treatment and, 318–319
- risk factors regarding, 320
- Lisinopril (Zestril, Prinivil), 78
  - CHF and, 29
  - diluents/concentrations, 88
  - indication/mechanism, 85
  - liver disease and, 26
  - mechanism of action, 78, 85
  - pharmacokinetics/monitoring parameters, 86
  - warnings/drug interactions, 87
- Lithium
  - acetazolamide and, 136
  - amiloride and, 134
  - mannitol and, 137
  - vasopressin and, 57
- Liver disease
  - cardiovascular agents in, 26–27
  - pharmacokinetics regarding, 25–27
- Loop diuretics
  - bumetanide, 122–124
  - ethacrynic acid, 125–127
  - furosemide, 120–122
  - torsemide, 124–125
- Lorazepam, 220
- Losartan (Cozaar)
  - CYP drug interactions and, 24
  - diluents/concentrations, 91
  - dosing/pharmacokinetics, 89
  - drug interactions, 90–91
  - indication, 88
  - mechanism of action, 78, 88–89
  - monitoring parameters/warnings, 90
- Lovastatin
  - CYP drug interactions and, 24
  - lipid lowering and, 322–325
- Low cardiac output status, 52
- Macrolides
  - CYP drug interactions and, 24
  - digoxin interactions with, 38
- Magnesium sulfate, 185–187
- Maintenance therapy. *See specific drug*
- Mammalian target of rapamycin, 190, 191, 202–204
- Mannitol
  - diluents, 138
  - dosing, 136–137
  - indication/mechanism of action, 136
  - pharmacokinetics/warnings/drug interactions, 137
- MAO inhibitors
  - dopamine and, 43
  - dopexamine and, 44–45
  - metaraminol and, 61
  - norepinephrine and, 51
- Mean velocity of circumferential fiber shortening (Vcf), 11
- Mechanism of action. *See specific drug*
- Medication errors
  - ADRs in children and, 338–340
  - basic prevention concepts and, 336
  - causes of, 334, 335, 336
  - CPOE and, 334, 335–336
  - do not use list and, 338
  - dosage regarding, 334
  - high risk-high alert drugs and, 335, 336
  - intensive care units and, 335
  - JCAHO safety goals and, 337
  - statistics on, 334, 335
- Meperidine
  - critical care settings and, 29
  - renal disease and, 27
- Metabolism, 20, 29–30
- Metaraminol
  - adverse effects/diluents, 62
  - drug interactions, 61–62
  - indication, 60
  - mechanisms/dosing/pharmacokinetics, 61
- Methyldopa, 28
- Methylprednisolone
  - CYP drug interactions and, 24
  - heart transplantation and, 190–193
- Methyltransferase, 30
- Metolazone, 130–131
- Metoprolol
  - as  $\beta$ -blocker, 140–142, 167–169
  - as class II antiarrhythmic, 167–169
  - CYP drug interactions and, 23
  - hydralazine and, 119
  - nicardipine and, 100
- Mexiletine
  - CHF and, 29
  - as class IB antiarrhythmic, 157–158
  - liver disease and, 26
- Midazolam
  - critical care settings and, 30
  - CYP drug interactions and, 24
  - ECMO and, 220–221
  - rectal absorption and, 18
  - renal disease and, 27
  - as sedative hypnotic/anesthetic agent, 307–310

- Milrinone  
 compatible diluents, 55–56  
 critical care settings and, 29  
 ECMO and, 215  
 indication/mechanisms/dosing, 54  
 pharmacokinetics/drug interactions/  
 adverse effects, 55
- MOA inhibitors, 59
- Monitoring parameters. *See specific drug*
- Monoclonal antibodies, 190  
 alemtuzumab, 208–210  
 muromonab, 206–208
- Morphine  
 critical care settings and, 30  
 CYP drug interactions and, 24  
 ECMO and, 220  
 renal disease and, 27
- Muromonab, 206–208
- Mycophenolate mofetil, 190, 191, 200–202
- Myocardial cells, 1
- N-acetyl-procainamide  
 CHF and, 29  
 renal disease and, 28
- Nadolol  
 as class II antiarrhythmic, 169–170  
 renal disease and, 28
- Narcotic analgesics, 340
- Neonatal v. adult heart, 11–12
- Neuromuscular-blocking agents, 215
- Niacin (Nicotinic acid), 327–328
- Nicardipine (Cardene, Cardene I.V.,  
 Cardene SR)  
 critical care settings and, 29  
 diluents/concentrations, 100  
 dosing, 98  
 drug interactions, 24, 100  
 indication, 97  
 liver disease and, 26–27  
 mechanism of action, 78, 97  
 monitoring parameters, 99  
 pharmacokinetics, 98–99  
 warnings, 99–100
- Nicotinic acid. *See Niacin*
- Nifediac CC, Nifedical XL.  
*See Nifedipine*
- Nifedipine (Adalat CC, Afeditab, Nifediac  
 CC, Nifedical XL, Procardia,  
 Procardia XL)  
 CYP drug interactions and, 23, 24  
 diluents/concentrations, 94  
 dosing, 92  
 drug interactions, 93–94  
 indication, 91  
 mechanism of action, 78, 91–92  
 monitoring parameters/warnings, 93  
 pharmacokinetics, 92–93
- Nimodipine, 26–27
- Nipride. *See Nitroprusside*
- Nitrates/nitrate-like agents  
 advantages/disadvantages of, 227  
 nitroglycerin, 78, 101–104  
 nitroprusside, 78, 104–107
- Nitro-Bid, Nitro-Dur, Nitrogard,  
 Nitrol, Nitrostat, Nitro-Tab. *See*  
 Nitroglycerin
- Nitroglycerin (Nitro-Bid, Nitro-Dur,  
 Nitrogard, Nitrol, Nitrostat,  
 Nitro-Tab)  
 concentrations, 104  
 diluents, 103–104  
 dosing, 101–102  
 drug clearing and, 215  
 indication, 101  
 mechanism of action, 78, 101  
 pharmacokinetics/monitoring  
 parameters, 102  
 warnings/drug interactions, 103
- Nitroprusside (Nipride)  
 diluents/concentrations, 107  
 dosing, 104–105  
 drug interactions, 106  
 indication, 104  
 mechanism of action, 78, 104  
 pharmacokinetics/monitoring  
 parameters, 105  
 pulmonary hypertension and, 234  
 warnings, 105–106
- NO. *See Inhaled nitric oxide*
- Noradrenaline. *See Norepinephrine*
- Norepinephrine (Noradrenaline)  
 compatible diluents, 51–52  
 dopexamine and, 44–45  
 dosing, 50–51  
 indication/mechanisms, 50  
 pharmacokinetics/drug interactions/  
 adverse effects, 51  
 phenoxybenzamine and, 109  
 spironolactone and, 133
- Norvasc. *See Amlodipine*
- Omega-3 fatty acids, 329
- Opioids, 20–22
- Osmotic diuretics, 136–138
- Oxygen, 235, 238
- Oxytocic drugs  
 dopamine and, 43  
 phenylephrine and, 59

- Pacemaker cells, 3–4
- Pediatric heart
  - cardiac physiology regarding, 11–12
  - shunt lesions and, 12–15
- Penicillins, 19
- Percutaneous absorption, 17–18
- Pharmacogenomics, 30
- Pharmacokinetics. *See specific drug*
- Pharmacokinetics, pediatric
  - congestive heart failure and, 28–29
  - critical care settings and, 29–30
  - disease states altering, 25–29
  - drug absorption and, 17–18
  - drug distribution and, 18–19
  - drug elimination and, 20–25
  - liver disease and, 25–27
  - pharmacogenomics and, 30
  - renal disease and, 27–28
- Phenobarbital
  - acetazolamide and, 136
  - CYP drug interactions and, 24
  - ECMO and, 221
  - losartan and, 91
  - nicardipine and, 100
- Phenoxybenzamine
  - dosing/pharmacokinetics, 108
  - indication, 107
  - mechanism of action, 78, 108
  - pulmonary hypertension and, 234
  - warnings/drug interactions, 109
- Phentolamine
  - dosing, 111–112
  - indication, 110–111
  - mechanism of action, 78, 111
  - pharmacokinetics/warnings/drug interactions, 112
- Phenylephrine
  - adverse effects/diluents, 60
  - dosing/pharmacokinetics, 59
  - drug interactions, 59–60
  - indication/mechanisms, 58
- Phenytoin
  - acetazolamide and, 136
  - as class IB antiarrhythmic, 158–160
  - critical care settings and, 29
  - CYP drug interactions and, 24
  - dopamine and, 43
  - drug distribution and, 19
  - losartan and, 91
  - nicardipine and, 100
  - nifedipine and, 93
  - Vd and, 18
- Phosphodiesterase inhibitors
  - inamrinone/amrinone, 52–54
  - milrinone, 54–56
- pulmonary hypertension and,
  - 236, 237
- type III, advantages/disadvantages of,
  - 227–228
- type V
  - advantages/disadvantages of, 228
  - pulmonary hypertension and, 228, 239–240
- Poisoning information. *See specific drug*
- Polyclonal antibodies, 190, 204–206
- Postoperative LCOS, 54
- Potassium-sparing diuretics
  - amiloride, 133–134
  - spironolactone, 132–133
- Pravastatin
  - CYP drug interactions and, 24
  - lipid lowering and, 322–325
- Prazosin, 28
- Precautions. *See specific drug*
- Prednisone, 190–193
- Preload
  - cardiac physiology and, 3, 5–6, 7
  - Frank-Starling curve and, 7
  - pressure-volume loops and, 8, 9–10
- Pressure-volume loops, 8, 9–10
- Prinivil. *See Lisinopril*
- Procainamide
  - acetazolamide and, 136
  - CHF and, 29
  - diluents, 154
  - indication/mechanism/dosing, 152
  - liver disease and, 26
  - monitoring parameters/warnings/drug interactions, 153
  - pharmacokinetics, 152–153
  - renal disease and, 28
- Procardia, Procardia XL. *See Nifedipine*
- Propafenone
  - as class IC antiarrhythmic, 161–163
  - CYP drug interactions and, 25
  - liver disease and, 26
- Propofol
  - acetazolamide and, 136
  - critical care settings and, 29
  - ECMO and, 221
  - nicardipine and, 100
  - as sedative hypnotic/anesthetic agent, 280–284
- Propranolol
  - as  $\beta$ -blocker, 145–147, 164–166
  - as class II antiarrhythmic, 164–166
  - CYP drug interactions and, 23
  - drug distribution and, 19

- Propranolol (*Continued*)  
 hydralazine and, 119  
 liver disease and, 26  
 renal disease and, 27
- Prostacyclin, 230, 235–236, 237
- Prostaglandin E<sub>1</sub>  
 dosing, 115–116  
 drug interactions/diluents, 117  
 indication, 115  
 mechanism of action, 78, 115  
 pharmacokinetics/monitoring parameters, 116  
 warnings, 116–117
- Prostaglandins  
 advantages/disadvantages of, 227  
 prostaglandin E<sub>1</sub>, 78, 115–117
- Protamine, 272–274
- Protein-binding effects, 19
- Pulmonary hypertension  
 common therapeutic agents for, 230  
 inamrinone and, 52  
 inpatient treatment of acute,  
 229–237  
 inhaled NO and, 231–234,  
 235–237  
 intravenous vasodilators and, 234  
 introduction to, 229–231  
 other vasodilators and, 235–237  
 prostacyclin and, 230, 235
- isoproterenol/isoprenaline and, 48  
 milrinone and, 54  
 outpatient treatment of chronic/  
 idiopathic, 237–240  
 anticoagulation/oxygen/right heart  
 failure and, 238  
 calcium channel blockers/endothelin  
 receptor antagonists and, 239  
 type 5 phosphodiesterase inhibitors  
 and, 239–240  
 pathophysiology of, 226, 228–229  
 treatment literature on, 237  
 unique challenges surrounding,  
 237–238  
 vasodilators advantages/disadvantages  
 for, 226, 228–229
- Purkinje fibers, 1–2, 3
- Quinidine  
 acetazolamide and, 136  
 CHF and, 29  
 CYP drug interactions and, 23, 24, 25  
 diluents, 152  
 drug distribution and, 19  
 indication/mechanism/dosing, 150  
 liver disease and, 26  
 monitoring parameters/drug  
 interactions, 151  
 nifedipine and, 93  
 pharmacokinetics, 150–151  
 warnings, 151–152
- Quinolones  
 calcium chloride and, 64  
 critical care settings and, 29
- Rabbit antithymocyte globulin  
 (Thymoglobulin), 204–206
- Ramipril, 29
- Ranitidine, 215
- Rapamycin. *See* Mammalian target of  
 rapamycin
- Rectal absorption, 18
- Remifentanil, 300–303
- Renal disease, 27–28
- Reserpine  
 phenoxybenzamine and, 109  
 renal disease and, 28
- Resting potentials, 2–3
- Rifampin  
 amlodipine and, 96  
 CYP drug interactions and, 23, 24  
 losartan and, 91  
 nifedipine and, 100
- Rosuvastatin, 322–325
- SA. *See* Sinoatrial node
- Salicylates  
 acetazolamide and, 136  
 drug distribution and, 19
- Sedative hypnotic agents  
 ADRs and, 340  
 dexmedetomidine, 294–300  
 etomidate, 284–288  
 fentanyl, 303–306  
 halothane/isoflurane/sevoflurane/  
 desflurane, 310–314  
 ketamine, 289–294  
 midazolam, 307–310  
 propofol, 280–284  
 remifentanil, 300–303
- Sevoflurane  
 correlated with age, 311  
 drug interactions, 313  
 indication/dosing, 310  
 pharmacokinetics, 312  
 poisoning/diluents, 314  
 systemic/adverse effects, 312–313
- SF. *See* Shortening fraction
- Shortening fraction (SF), 11

- Shunt lesions  
  hemodynamic calculations regarding,  
    13–15  
  nature of, 12–13
- Sildenafil  
  CYP drug interactions and, 25  
  nitroglycerin and, 103  
  pulmonary hypertension and,  
    236–237, 239–240
- Simvastatin  
  CYP drug interactions and, 24  
  lipid lowering and, 322–325
- Sinoatrial (SA) node, 1, 2
- Sirolimus, 190, 191, 202–204
- Sotalol  
  dosing, 174–175  
  indication/mechanism, 173  
  pharmacokinetics/monitoring/drug  
    interactions, 175  
  renal disease and, 28  
  warnings, 175–176
- Spironolactone, 132–133
- Sulfonamides, 19
- Systemic hypertension  
  amlodipine and, 94  
  captopril and, 78  
  enalapril/enalaprilat and, 81  
  fenoldopam and, 113  
  lisinopril and, 85  
  losartan and, 88  
  nifedipine and, 91
- Systemic vascular resistance (SVR), 6
- Systemic vasodilators  
  phenoxybenzamine, 78, 107–109  
  phentolamine, 78, 110–112
- Tachyarrhythmias, 4–5, 35–36
- Tacrolimus  
  amiloride and, 134  
  heart transplantation and, 190–191,  
    196–198
- Theophylline  
  CYP drug interactions and, 24  
  isoproterenol and, 49  
  liothyronine and, 66
- Thiazide/thiazide-like diuretics  
  calcium chloride and, 64  
  chlorothiazide, 127–129  
  hydrochlorothiazide, 129–130  
  metolazone, 130–131
- Thiopurine, 30
- Third-degree AV block, 48
- Thromboembolism, 238
- Thromboxane inhibitors, 237
- Thymoglobulin. *See* Rabbit  
  antithymocyte globulin
- Timolol, 23
- Tocainide  
  CHF and, 29  
  liver disease and, 26
- Tolazoline, 234
- Torsemide, 124–125
- Tranexamic acid, 274–275
- Transplantation, heart  
  antibodies to IL2R and, 190, 210–213  
    basiliximab, 210–212  
    daclizumab, 212–213  
  antimetabolites and, 190, 191, 198–202  
    AZA, 190, 191, 198–200  
    mycophenolate mofetil, 190, 191,  
      200–202  
  CNIs and, 190, 193–198  
    cyclosporine, 190, 191, 193–196  
    tacrolimus, 190, 191, 196–198  
  corticosteroids and,  
    methylprednisolone/prednisone,  
      190–193  
  induction/maintenance therapy  
    options for, 191  
  introduction to, 190  
  mammalian target of rapamycin,  
    sirolimus, 202–204  
  monoclonal antibodies, 190, 206–210  
    alemtuzumab, 208–210  
    muromonab, 206–208  
  polyclonal antibodies, thymoglobulin  
    atgam, 204–206
- Triazolam, 24
- Tricyclic antidepressant drugs  
  acetazolamide and, 136  
  dopamine and, 43  
  epinephrine and, 47  
  metaraminol and, 61  
  norepinephrine and, 51  
  vasopressin and, 57
- Valproate, 19
- Valproic acid, 19
- Valsartan, 26
- Vancomycin  
  ECMO and, 218  
  renal excretion and, 25
- Vasoactive drugs  
  introduction to, 33–35, 36  
  metaraminol, 60–62  
  phenylephrine, 58–60
- Vasoactive drugs  
  vasopressin, 56–58

## Vasodilators

## Vasodilators

ACE inhibitors, 78–88

captopril, 78–81

enalapril, 78, 81–84

lisinopril, 78, 85–88

adrenoceptor antagonists, 78, 107–112

phenoxybenzamine, 78, 107–109

phentolamine, 78, 110–112

angiotensin II receptor blockers,

losartan, 78, 88–91

calcium channel blockers, 78, 91–100

amlodipine, 78, 94–97

nicardipine, 78, 97–100

nifedipine, 78, 91–94

classification of, 78

dopaminergic receptor agonists,

fenoldopam, 78, 113–115

hydralazine, 78, 117–119

inhaled NO, 228, 230, 231–234, 235–237

intravenous, 234

introduction to, 77–78

nitrates/nitrate-like agents, 78, 101–107

nitroglycerin, 78, 101–104

nitroprusside, 78, 104–107

prostacyclin, 230, 235

prostaglandins, prostaglandin E<sub>1</sub>, 78,

115–117

## Vasopressin

adverse effects, 57–58

critical care settings and, 30

dosing, 56–57

indication/mechanisms, 56

pharmacokinetics/drug interactions, 57

poisoning/compatible diluents, 58

renal disease and, 27

Vasotec. *See* EnalaprilVcf. *See* Mean velocity of circumferential

fiber shortening

Vd. *See* Volume of distribution

Verapamil

as class IV antiarrhythmic, 179–181

critical care settings and, 29

CYP drug interactions and, 23–24

liver disease and, 26–27

Volume of distribution (Vd), 18–19,

215–216, 217

## Warfarin

as anticoagulant/antithrombotic/

antiplatelet, 275–278

drug distribution and, 19

ethacrynic acid and, 127

furosemide and, 121

losartan and, 91

pulmonary hypertension and, 238

torsemide and, 125

Warnings. *See specific drug*

Young child v. adult heart, 12

Zestril. *See* Lisinopril